ASH Highlights: Efgartigimod Safe and Effective in Treating Immune Thrombocytopenia (ITP) |

Adrian C. Newland, MD, of the Royal London Hospital in London, U.K. provided an update on the Phase 2 clinical trial looking at the safety and efficacy of efgartigimod to treat primary immune thrombocytophenia (ITP).

Read the full article here

Related Articles